(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Syndax Pharmaceuticals's revenue in 2024 is $0.On average, 4 Wall Street analysts forecast SNDX's revenue for 2024 to be $2,834,958,406, with the lowest SNDX revenue forecast at $559,922,553, and the highest SNDX revenue forecast at $6,882,204,366. On average, 4 Wall Street analysts forecast SNDX's revenue for 2025 to be $8,172,065,409, with the lowest SNDX revenue forecast at $6,278,949,415, and the highest SNDX revenue forecast at $12,566,395,379.
In 2026, SNDX is forecast to generate $18,718,236,428 in revenue, with the lowest revenue forecast at $15,626,852,185 and the highest revenue forecast at $26,867,785,983.